Report post
BMY stock is experiencing a significant decline, reaching a 52-week low. However, analysts predict a massive upside potential. This biotech stock offers both risks and rewards, with a Jefferies expert forecasting a biotech boom in 2024. Despite the crash, BMY remains undervalued with a 4.7% yield, making it a potential buy for investors.

The World's Leading Crypto Trading Platform

Get my welcome gifts